Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| MAD | Other Identifier | Alias Study Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is the first clinical trial to evaluate ascending multiple oral doses in healthy adult and healthy elderly subjects to characterize the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BIIB118
This study was previously posted by Pfizer. In March, 2020, sponsorship of the trial was transferred to Biogen.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Multiple Doses - Part A | Experimental | Multiple ascending doses administered in the morning to healthy adult subjects in a parallel study design |
|
| Multiple Dose - Part B | Experimental | Multiple ascending doses administered in the evening to healthy adult subjects in a parallel study design |
|
| Multiple Doses - Elderly | Experimental | Multiple ascending doses administered to elderly subjects |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BIIB118 | Drug | Multiple ascending doses of BIIB118 (50 mg, 150 mg, 450 mg and 900 mg) as extemporaneously prepared solution/suspension administered once daily over 2 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline for Bond and Lader Visual Analogue Scale (BL-VAS) on Days 1, 4, 7, 10, 14, 15 and 16 - Alertness | The Bond and Lader Visual Analogue Scales (VAS) monitored the subjective mood of each participant on 16 mood scales. Participants were asked to indicate on the VAS scale ranging from 0 to 100 mm about how they felt at the moment the scale was administered (example, alert/drowsy; calm/excited; content/tensed). The individual responses from the 16 mood scales were then combined to make three affective dimensions/subscales a) alertness (average of 9 items [total range 0 to 100, where each item is ordered so that higher scores indicated more alertness]), b) mood (average of 2 items [total range 0 to 100, where higher scores indicated elevated mood]), and c) calmness (average of 5 items [total range 0 to 100, where higher scores indicated more calmness]). Baseline is defined as the last available recording prior to dosing on Day 1. | Baseline (0h on Day 1), Day 1 (2h), Day 4 (1.5h), Day 7 (0h, 2h), Day 10 (1.5h), Day 14 (0h, 2h), Day 15 (0h) and Day 16 (0h). |
| Change From Baseline for Bond and Lader Visual Analogue Scale (BL-VAS) on Days 1, 4, 7, 10, 14, 15 and 16 - Calmness | The Bond and Lader Visual Analogue Scales (VAS) monitored the subjective mood of each participant on 16 mood scales. Participants were asked to indicate on the VAS scale ranging from 0 to 100 mm about how they felt at the moment the scale was administered (example, alert/drowsy; calm/excited; content/tensed). The individual responses from the 16 mood scales were then combined to make three affective dimensions/subscales a) alertness (average of 9 items [total range 0 to 100, where each item is ordered so that higher scores indicated more alertness]), b) mood (average of 2 items [total range 0 to 100, where higher scores indicated elevated mood]), and c) calmness (average of 5 items [total range 0 to 100, where higher scores indicated more calmness]). Baseline is defined as the last available recording prior to dosing on Day 1. | Baseline (0h on Day 1), Day 1 (2h), Day 4 (1.5h), Day 7 (0h, 2h), Day 10 (1.5h), Day 14 (0h, 2h), Day 15 (0h) and Day 16 (0h). |
| Change From Baseline for Bond and Lader Visual Analogue Scale (BL-VAS) on Days 1, 4, 7, 10, 14, 15 and 16- Mood |
| Measure | Description | Time Frame |
|---|---|---|
| Maximum Plasma Concentration (Cmax) of PF-05251749 - Days 1, 7 and 14 | Maximum plasma concentration (Cmax) of PF-05251749 was observed directly from data on Days 1, 7 and 14. | Days 1 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h), 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h). |
Not provided
Inclusion Criteria:
Healthy male and/or female subjects of non-childbearing potential between the ages of 18 and 55 years (Parts A and B) or 65 and 85 years (Part C), inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).
Female subjects of non-childbearing potential must meet at least one of the following criteria:
Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Biogen | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| QPS-MRA, LLC (Miami Research Associates) | South Miami | Florida | 33143 | United States | ||
| Qps-Mra, Llc |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35730131 | Derived | Lin J, Gaudreault F, Johnson N, Lin Z, Nouri P, Goosen TC, Sawant-Basak A. Investigation of CYP3A induction by PF-05251749 in early clinical development: comparison of linear slope physiologically based pharmacokinetic prediction and biomarker response. Clin Transl Sci. 2022 Sep;15(9):2184-2194. doi: 10.1111/cts.13352. Epub 2022 Jul 2. |
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Placebo (Part A) | Participants received placebo suspensions matched to PF-05251749 at 08:00 AM after an overnight fast on Days 1, 7, 14 (other doses were administered outside a window of ±2 hours of giving food), and also received placebo capsules matched to melatonin at 06:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| FG001 | Melatonin 0.5 mg PM (Part A) | Participants received placebo suspensions matched to PF-05251749 at 08:00 AM after an overnight fast on Days 1, 7, 14 (other doses were administered outside a window of ±2 hours of giving food), and also received melatonin 0.5 mg at 06:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| FG002 | PF-05251749 50 mg AM (Part A) | Participants received PF-05251749 50 mg orally at 08:00 AM after an overnight fast on Days 1, 7, 14 (other doses were administered outside a window of ±2 hours of giving food), and also received placebo capsules matched to melatonin at 06:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| FG003 | PF-05251749 100 mg AM (Part A) | Participants received PF-05251749 100 mg orally at 08:00 AM after an overnight fast on Days 1, 7, 14 (other doses were administered outside a window of ±2 hours of giving food), and also received placebo capsules matched to melatonin at 06:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| FG004 | PF-05251749 200 mg AM (Part A) | Participants received PF-05251749 200 mg orally at 08:00 AM after an overnight fast on Days 1, 7, 14 (other doses were administered outside a window of ±2 hours of giving food), and also received placebo capsules matched to melatonin at 06:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| FG005 | PF-05251749 400 mg AM (Part A) | Participants received PF-05251749 400 mg orally at 08:00 AM after an overnight fast on Days 1, 7, 14 (other doses were administered outside a window of ±2 hours of giving food), and also received placebo capsules matched to melatonin at 06:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| FG006 | PF-05251749 750 mg AM (Part A) | Participants received PF-05251749 750 mg orally at 08:00 AM after an overnight fast on Days 1, 7, 14 (other doses were administered outside a window of ±2 hours of giving food), and also received placebo capsules matched to melatonin at 06:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| FG007 | Placebo (Part B) | Participants received placebo suspensions matched to PF-05251749 at 6:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| FG008 | PF-05251749 50 mg PM (Part B) | Participants received PF-05251749 50 mg orally at 6:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| FG009 | PF-05251749 200 mg PM (Part B) | Participants received PF-05251749 200 mg orally at 6:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| FG010 | PF-05251749 500 mg PM (Part B) | Participants received PF-05251749 500 mg orally at 6:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Baseline analysis population included all participants enrolled.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Placebo (Part A) | Participants received placebo suspensions matched to PF-05251749 at 08:00 AM after an overnight fast on Days 1, 7, 14 (other doses were administered outside a window of ±2 hours of giving food), and also received placebo capsules matched to melatonin at 06:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Number |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline for Bond and Lader Visual Analogue Scale (BL-VAS) on Days 1, 4, 7, 10, 14, 15 and 16 - Alertness | The Bond and Lader Visual Analogue Scales (VAS) monitored the subjective mood of each participant on 16 mood scales. Participants were asked to indicate on the VAS scale ranging from 0 to 100 mm about how they felt at the moment the scale was administered (example, alert/drowsy; calm/excited; content/tensed). The individual responses from the 16 mood scales were then combined to make three affective dimensions/subscales a) alertness (average of 9 items [total range 0 to 100, where each item is ordered so that higher scores indicated more alertness]), b) mood (average of 2 items [total range 0 to 100, where higher scores indicated elevated mood]), and c) calmness (average of 5 items [total range 0 to 100, where higher scores indicated more calmness]). Baseline is defined as the last available recording prior to dosing on Day 1. | The safety analysis set included all participants who received at least 1 dose of study treatment. | Posted | Mean | Standard Deviation | Units on a scale | Baseline (0h on Day 1), Day 1 (2h), Day 4 (1.5h), Day 7 (0h, 2h), Day 10 (1.5h), Day 14 (0h, 2h), Day 15 (0h) and Day 16 (0h). |
Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14).
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Placebo (Part A) | Participants received placebo suspensions matched to PF-05251749 at 08:00 AM after an overnight fast on Days 1, 7, 14 (other doses were administered outside a window of ±2 hours of giving food), and also received placebo capsules matched to melatonin at 06:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Atrial fibrillation | Cardiac disorders | MedDRA 20.0 | Non-systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Thrombocytosis | Blood and lymphatic system disorders | MedDRA 20.0 | Non-systematic Assessment |
From Parts A and B, it was deemed that safety, tolerability, PK and PD objectives were met, so Part C was not conducted. Because of limited saliva sampling duration (06:00 PM to 12:00 AM), DLMO observation(s) beyond midnight could not be quantified.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Pfizer ClinicalTrials.gov Call Center | Pfizer, Inc. | 1-800-718-1021 | ClinicalTrials.gov_Inquiries@pfizer.com |
Not provided
| ID | Term |
|---|---|
| D008550 | Melatonin |
| ID | Term |
|---|---|
| D014363 | Tryptamines |
| D007211 | Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Melatonin | Drug | Positive control used to assess the validity of DLMO as pharmacodynamic endpoint. |
|
The Bond and Lader Visual Analogue Scales (VAS) monitored the subjective mood of each participant on 16 mood scales. Participants were asked to indicate on the VAS scale ranging from 0 to 100 mm about how they felt at the moment the scale was administered (example, alert/drowsy; calm/excited; content/tensed). The individual responses from the 16 mood scales were then combined to make three affective dimensions/subscales a) alertness (average of 9 items [total range 0 to 100, where each item is ordered so that higher scores indicated more alertness]), b) mood (average of 2 items [total range 0 to 100, where higher scores indicated elevated mood]), and c) calmness (average of 5 items [total range 0 to 100, where higher scores indicated more calmness]). Baseline is defined as the last available recording prior to dosing on Day 1.
| Baseline (0h on Day 1), Day 1 (2h), Day 4 (1.5h), Day 7 (0h, 2h), Day 10 (1.5h), Day 14 (0h, 2h), Day 15 (0h) and Day 16 (0h). |
| Number of Participants With New Onset and Worsening of Post-baseline Suicidality for Columbia Suicide Severity Rating Scale (C-SSRS) | The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of "yes" on "actual attempt"), 3: preparatory acts toward imminent suicidal behavior ("yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), 4: any suicidal behavior or ideation, suicidal ideation ("yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent"), 7: self-injurious behavior, no suicidal intent ("yes" on "has participant engaged in non-suicidal self-injurious behavior"). The new onset and worsening of post-baseline suicidality for C-SSRS was reported. | Days 0, 7, 14, 16, and follow-up visit (28 calender days after the last dose of investigational product on Day 14). |
| Number of Participants With Treatment-Emergent Adverse Events (AEs) (All Causalities) | An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. | Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14). |
| Number of Participants With Treatment-Emergent Adverse Events (AEs) (Treatment Related) | An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; The event has a causal relationship with the treatment or usage. | Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14). |
| Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality) | The laboratory test included: hematology (hemoglobin, hematocrit, red blood cell count, MCV, MCH, MCHC, platelets, white blood cell count, absolute lymphocytes, absolute total neutrophils, absolute basophils, absolute eosinophils and absolute monocytes), coagulation (PPT, prothrombin, PT international, ratio and fibrinogen, liver function(total bilirubin, direct bilirubin, aspartate, AST, Alanine, ALT, gamma GT, alkaline phosphatase, total protein and albumin), renal function (blood urea nitrogen, creatinine, HDL cholesterol, LDL cholesterol, triglycerides), Electrolytes (sodium, potassium, chloride, calcium, phosphate, venous bicarbonate), clinical chemistry (glucose, creatinine kinase), urinalysis dipstick (urine PH, urine glucose, urine ketones, urine protein, urine blood, urine urobilinogen, urine nitrite, urine leukocyte, esterase), urinalysis microscopy (urine RBC, urine WBC, urine casts, urine bacteria), miscellaneous (absolute lymphocyte marker CD4, CD8, CD19) | Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14). |
| Number of Participants With Vital Signs Data Meeting Categorical Criteria (Absolute Values) | Number of participants with vital signs data of absolute values meeting categorical criteria was reported as following: (1) Supine systolic BP < 90 mmHg; (2) Supine Diastolic BP < 50 mmHg; (3) Supine Pulse Rate < 40 BPM ; (4) Supine Pulse Rate > 120 BPM. | Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14). |
| Number of Participants With Vital Signs Data Meeting Categorical Criteria (Increases From Baseline) | Number of participants with vital signs data of increase from baseline meeting the following criteria was reported: Criterion A: maximum increase from baseline in supine systolic BP >= 30 mmHg; Criterion B: maximum increase from baseline in supine diastolic BP >= 20 mmHg. Baseline was defined as the last available recording prior to dosing. | Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14). |
| Number of Participants With Vital Signs Data Meeting Categorical Criteria (Decrease From Baseline) | Number of participants with vital signs data of increase from baseline meeting the following criteria was reported: Criterion A: maximum decrease from baseline in supine systolic BP >= 30 mmHg; Criterion B: maximum decrease from baseline in supine diastolic BP >= 20 mmHg. Baseline was defined as the last available recording prior to dosing. | Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14). |
| Number of Participants With Electrocardiogram (ECG) Data Meeting Categorical Criteria (Absolute Values) | Number of participants with ECG data of absolute values meeting categorical criteria was reported as following: Criterion A: maximum PR interval (time from the beginning of P wave to the start of QRS complex, corresponding to the end of atrial depolarization and onset of ventricular depolarization) >= 300 msec; Criterion B: maximum QRS complex (time from Q wave to the end of S wave, corresponding to ventricle depolarization)>= 140 msec; Criterion C: Maximum QT interval (time from the beginning of Q wave to the end of T wave corresponding to electrical systole)>= 500 msec; Criterion D: maximum QTC interval (QT interval corrected for heart rate) 450-<480 msec; Criterion E: maximum QTC interval 480-<500 msec; Criterion F: maximum QTC interval >=500 msec; Criterion G: maximum QTCF interval (QT interval corrected for heart rate using Fridericia's formula) 450 -< 480 msec; Criterion H: maximum QTCF interval 480 -< 500 msec; Criterion I: maximum QTCF interval >=500 msec. | Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14). |
| Number of Participants With Electrocardiogram (ECG) Data Meeting Categorical Criteria (Increase From Baseline) | Number of participants with ECG Data of increase from baseline meeting the following criteria was reported: Criterion A: maximum PR interval increase from baseline percentage change (PctChg)>=25/50%; Criterion B: maximum QRS complex increase from baseline PctChg >=50%; Criterion C: maximum QTC interval (time from the beginning of Q wave to the end of T wave corresponding to electrical systole, corrected for heart rate) increase from baseline 30<=change<60 msec; Criterion D: maximum QTC interval increase from baseline change >=60 msec; Criterion E: maximum QTCF (Fridericia's correction) interval increase from baseline 30<=change<60; Criterion F: maximum QTCF interval increase from baseline change >=60 msec. Baseline was defined as the average of the triplicate measurements prior to dosing on Day 1. | Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14). |
| Number of Participants With New/Intensified Physical Examination Findings | Physical examination included examination of ears, eyes, gastrointestinal, head, heart, lungs, lymph nodes, mouth, musculoskeletal, nose, skin. The number of participants with new-intensified physical examination findings were reported. | Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14). |
| Number of Participants With New/Intensified Neurological Examination Findings | The number of participants with new-intensified neurological examination findings were reported. | Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14). |
| Area Under the Concentration-Time Profile From Time 0 to Tau (AUCtau) of PF-05251749 - Days 1, 7 and 14. |
AUCtau referred to the area under the curve from time 0 to time tau, the dosing interval, where tau equaled to 24 hours on Days 1, 7 and 14. |
| Days 1 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h), 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h). |
| Time at Which Cmax Occurred (Tmax) of PF-05251749 - Days 1, 7 and 14 | Tmax of PF-05251749 was observed directly from data on Days 1, 7 and 14, as time of first occurrence. | Days 1 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h), 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h). |
| Apparent Clearance (CL/F) of PF-05251749 - Days 7 and 14 | Apparent clearance was influenced by the fraction of the dose absorbed, which was measured by Dose/AUCtau. | Days 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h). |
| Minimum Concentration Observed (Cmin) of PF-05251749 - Days 7 and 14 | Minimum concentration observed (Cmin) of PF-05251749 was observed directly from data on Days 7 and 14. | Days 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h). |
| Plasma Peak-to-trough Ratio (PTR) (Cmax/Cmin) of PF-05251749 - Days 7 and 14 | Peak-to-through ratio (PTR) was the ratio of Cmax to Cmin, which was measured on Days 7 and 14. | Days 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h). |
| Observed Accumulation Ratio (Rac) of PF-05251749 -Days 7 and 14 | Observed accumulation ratio (Rac) was calculated as AUCtau (Days 7 or 14) divided by AUCtau (Day 1). | Days 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h). |
| Observed Accumulation Ratio for Cmax (Rac,Cmax) of PF-05251749 - Days 7 and 14 | Observed accumulation ratio for Cmax (Rac,Cmax) was calculated as: Cmax on Day 7 or 14 divided by Cmax on Day 1. | Days 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h). |
| Terminal Half-Life (t1/2) of PF-05251749 - Day 14 | Terminal half-life (t1/2) was calculated as Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration time curve. | Day 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h). |
| Apparent Volume of Distribution (Vz/F) of PF-05251749 - Day 14 | Apparent volume of distribution (Vz/F) was calculated by Dose/(AUCtau × kel) on Day 14. | Day 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h). |
| Cumulative Amount of Drug Recovered Unchanged in Urine Over Dosing Interval Tau (Aetau) of PF-05251749 - Day 14 | Aetau was the cumulative amount of drug recovered unchanged in urine from time 0 to end of the dosing interval, which was calculated by sum of (urine concentration × volume of urine). | Day 14 (0, 0.5, 1, 1.5, 2, 3, 4, 5, 8, 12, 16, 20, 24, 48h). |
| Percentage of Dose Recovered Unchanged in Urine Over Dosing Interval Tau (Aetau%) of PF-05251749 - Day 14 | Aetau% was the percentage of dose recovered unchanged into urine from 0 to end of the dosing interval, which was calculated by 100 × Aetau/Dose. | Day 14 (0, 0.5, 1, 1.5, 2, 3, 4, 5, 8, 12, 16, 20, 24, 48h). |
| Renal Clearance (CLr) of PF-05251749 - Day 14 | Renal clearance was calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Ae) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau), Aetau/AUCtau. | Day 14 (0, 0.5, 1, 1.5, 2, 3, 4, 5, 8, 12, 16, 20, 24, 48h). |
| Change From Baseline for Dim Light Melatonin Onset (DLMO) Time - Day 6 | Dim Light Melatonin Onset (DLMO) was defined as point in time when the smooth melatonin curve exceeds the threshold. The threshold for each melatonin profile was calculated as the mean of three low consecutive daytime values (raw data points) plus twice the standard deviation of these points. | Day 0 (Baseline) and Day 6. |
| Change From Baseline for Dim Light Melatonin Onset (DLMO) Time - Day 15 | DLMO was defined as point in time when the smooth melatonin curve exceeds the threshold. The threshold for each melatonin profile was calculated as the mean of three low consecutive daytime values (raw data points) plus twice the standard deviation of these points. | Day 0 (Baseline) and Day 15 |
| South Miami |
| Florida |
| 33143 |
| United States |
| Lost to Follow-up |
|
| Withdrawal by Subject |
|
| Other |
|
| Protocol Violation |
|
| BG001 | Melatonin 0.5 mg PM (Part A) | Participants received placebo suspensions matched to PF-05251749 at 08:00 AM after an overnight fast on Days 1, 7, 14 (other doses were administered outside a window of ±2 hours of giving food), and also received melatonin 0.5 mg at 06:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| BG002 | PF-05251749 50 mg AM (Part A) | Participants received PF-05251749 50 mg orally at 08:00 AM after an overnight fast on Days 1, 7, 14 (other doses were administered outside a window of ±2 hours of giving food), and also received placebo capsules matched to melatonin at 06:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| BG003 | PF-05251749 100 mg AM (Part A) | Participants received PF-05251749 100 mg orally at 08:00 AM after an overnight fast on Days 1, 7, 14 (other doses were administered outside a window of ±2 hours of giving food), and also received placebo capsules matched to melatonin at 06:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| BG004 | PF-05251749 200 mg AM (Part A) | Participants received PF-05251749 200 mg orally at 08:00 AM after an overnight fast on Days 1, 7, 14 (other doses were administered outside a window of ±2 hours of giving food), and also received placebo capsules matched to melatonin at 06:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| BG005 | PF-05251749 400 mg AM (Part A) | Participants received PF-05251749 400 mg orally at 08:00 AM after an overnight fast on Days 1, 7, 14 (other doses were administered outside a window of ±2 hours of giving food), and also received placebo capsules matched to melatonin at 06:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| BG006 | PF-05251749 750 mg AM (Part A) | Participants received PF-05251749 750 mg orally at 08:00 AM after an overnight fast on Days 1, 7, 14 (other doses were administered outside a window of ±2 hours of giving food), and also received placebo capsules matched to melatonin at 06:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| BG007 | Placebo (Part B) | Participants received placebo suspensions matched to PF-05251749 at 6:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| BG008 | PF-05251749 50 mg PM (Part B) | Participants received PF-05251749 50 mg orally at 6:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| BG009 | PF-05251749 200 mg PM (Part B) | Participants received PF-05251749 200 mg orally at 6:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| BG010 | PF-05251749 500 mg PM (Part B) | Participants received PF-05251749 500 mg orally at 6:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| BG011 | Total | Total of all reporting groups |
| participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| ID | Title | Description |
|---|
| OG000 | Placebo (Part A) | Participants received placebo suspensions matched to PF-05251749 at 08:00 AM after an overnight fast on Days 1, 7, 14 (other doses were administered outside a window of ±2 hours of giving food), and also received placebo capsules matched to melatonin at 06:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| OG001 | Melatonin 0.5 mg PM (Part A) | Participants received placebo suspensions matched to PF-05251749 at 08:00 AM after an overnight fast on Days 1, 7, 14 (other doses were administered outside a window of ±2 hours of giving food), and also received melatonin 0.5 mg at 06:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| OG002 | PF-05251749 50 mg AM (Part A) | Participants received PF-05251749 50 mg orally at 08:00 AM after an overnight fast on Days 1, 7, 14 (other doses were administered outside a window of ±2 hours of giving food), and also received placebo capsules matched to melatonin at 06:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| OG003 | PF-05251749 100 mg AM (Part A) | Participants received PF-05251749 100 mg orally at 08:00 AM after an overnight fast on Days 1, 7, 14 (other doses were administered outside a window of ±2 hours of giving food), and also received placebo capsules matched to melatonin at 06:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| OG004 | PF-05251749 200 mg AM (Part A) | Participants received PF-05251749 200 mg orally at 08:00 AM after an overnight fast on Days 1, 7, 14 (other doses were administered outside a window of ±2 hours of giving food), and also received placebo capsules matched to melatonin at 06:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| OG005 | PF-05251749 400 mg AM (Part A) | Participants received PF-05251749 400 mg orally at 08:00 AM after an overnight fast on Days 1, 7, 14 (other doses were administered outside a window of ±2 hours of giving food), and also received placebo capsules matched to melatonin at 06:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| OG006 | PF-05251749 750 mg AM (Part A) | Participants received PF-05251749 750 mg orally at 08:00 AM after an overnight fast on Days 1, 7, 14 (other doses were administered outside a window of ±2 hours of giving food), and also received placebo capsules matched to melatonin at 06:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| OG007 | Placebo (Part B) | Participants received placebo suspensions matched to PF-05251749 at 6:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| OG008 | PF-05251749 50 mg PM (Part B) | Participants received PF-05251749 50 mg orally at 6:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| OG009 | PF-05251749 200 mg PM (Part B) | Participants received PF-05251749 200 mg orally at 6:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
| OG010 | PF-05251749 500 mg PM (Part B) | Participants received PF-05251749 500 mg orally at 6:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. |
|
|
| Primary | Change From Baseline for Bond and Lader Visual Analogue Scale (BL-VAS) on Days 1, 4, 7, 10, 14, 15 and 16 - Calmness | The Bond and Lader Visual Analogue Scales (VAS) monitored the subjective mood of each participant on 16 mood scales. Participants were asked to indicate on the VAS scale ranging from 0 to 100 mm about how they felt at the moment the scale was administered (example, alert/drowsy; calm/excited; content/tensed). The individual responses from the 16 mood scales were then combined to make three affective dimensions/subscales a) alertness (average of 9 items [total range 0 to 100, where each item is ordered so that higher scores indicated more alertness]), b) mood (average of 2 items [total range 0 to 100, where higher scores indicated elevated mood]), and c) calmness (average of 5 items [total range 0 to 100, where higher scores indicated more calmness]). Baseline is defined as the last available recording prior to dosing on Day 1. | The safety analysis set included all participants who received at least 1 dose of study treatment. | Posted | Mean | Standard Deviation | Units on a scale | Baseline (0h on Day 1), Day 1 (2h), Day 4 (1.5h), Day 7 (0h, 2h), Day 10 (1.5h), Day 14 (0h, 2h), Day 15 (0h) and Day 16 (0h). |
|
|
|
| Primary | Change From Baseline for Bond and Lader Visual Analogue Scale (BL-VAS) on Days 1, 4, 7, 10, 14, 15 and 16- Mood | The Bond and Lader Visual Analogue Scales (VAS) monitored the subjective mood of each participant on 16 mood scales. Participants were asked to indicate on the VAS scale ranging from 0 to 100 mm about how they felt at the moment the scale was administered (example, alert/drowsy; calm/excited; content/tensed). The individual responses from the 16 mood scales were then combined to make three affective dimensions/subscales a) alertness (average of 9 items [total range 0 to 100, where each item is ordered so that higher scores indicated more alertness]), b) mood (average of 2 items [total range 0 to 100, where higher scores indicated elevated mood]), and c) calmness (average of 5 items [total range 0 to 100, where higher scores indicated more calmness]). Baseline is defined as the last available recording prior to dosing on Day 1. | The safety analysis set included all participants who received at least 1 dose of study treatment. | Posted | Mean | Standard Deviation | Units on a scale | Baseline (0h on Day 1), Day 1 (2h), Day 4 (1.5h), Day 7 (0h, 2h), Day 10 (1.5h), Day 14 (0h, 2h), Day 15 (0h) and Day 16 (0h). |
|
|
|
| Primary | Number of Participants With New Onset and Worsening of Post-baseline Suicidality for Columbia Suicide Severity Rating Scale (C-SSRS) | The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of "yes" on "actual attempt"), 3: preparatory acts toward imminent suicidal behavior ("yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), 4: any suicidal behavior or ideation, suicidal ideation ("yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent"), 7: self-injurious behavior, no suicidal intent ("yes" on "has participant engaged in non-suicidal self-injurious behavior"). The new onset and worsening of post-baseline suicidality for C-SSRS was reported. | The safety analysis set included all participants who received at least 1 dose of study treatment. | Posted | Number | Participants | Days 0, 7, 14, 16, and follow-up visit (28 calender days after the last dose of investigational product on Day 14). |
|
|
|
| Primary | Number of Participants With Treatment-Emergent Adverse Events (AEs) (All Causalities) | An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. | The safety analysis set included all participants who received at least 1 dose of study treatment. | Posted | Number | Participants | Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14). |
|
|
|
| Primary | Number of Participants With Treatment-Emergent Adverse Events (AEs) (Treatment Related) | An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; The event has a causal relationship with the treatment or usage. | The safety analysis set included all participants who received at least 1 dose of study treatment. | Posted | Number | Participants | Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14). |
|
|
|
| Primary | Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality) | The laboratory test included: hematology (hemoglobin, hematocrit, red blood cell count, MCV, MCH, MCHC, platelets, white blood cell count, absolute lymphocytes, absolute total neutrophils, absolute basophils, absolute eosinophils and absolute monocytes), coagulation (PPT, prothrombin, PT international, ratio and fibrinogen, liver function(total bilirubin, direct bilirubin, aspartate, AST, Alanine, ALT, gamma GT, alkaline phosphatase, total protein and albumin), renal function (blood urea nitrogen, creatinine, HDL cholesterol, LDL cholesterol, triglycerides), Electrolytes (sodium, potassium, chloride, calcium, phosphate, venous bicarbonate), clinical chemistry (glucose, creatinine kinase), urinalysis dipstick (urine PH, urine glucose, urine ketones, urine protein, urine blood, urine urobilinogen, urine nitrite, urine leukocyte, esterase), urinalysis microscopy (urine RBC, urine WBC, urine casts, urine bacteria), miscellaneous (absolute lymphocyte marker CD4, CD8, CD19) | The safety analysis set included all participants who received at least 1 dose of study treatment. | Posted | Number | Participants | Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14). |
|
|
|
| Primary | Number of Participants With Vital Signs Data Meeting Categorical Criteria (Absolute Values) | Number of participants with vital signs data of absolute values meeting categorical criteria was reported as following: (1) Supine systolic BP < 90 mmHg; (2) Supine Diastolic BP < 50 mmHg; (3) Supine Pulse Rate < 40 BPM ; (4) Supine Pulse Rate > 120 BPM. | The safety analysis set included all participants who received at least 1 dose of study treatment. | Posted | Number | Participants | Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14). |
|
|
|
| Primary | Number of Participants With Vital Signs Data Meeting Categorical Criteria (Increases From Baseline) | Number of participants with vital signs data of increase from baseline meeting the following criteria was reported: Criterion A: maximum increase from baseline in supine systolic BP >= 30 mmHg; Criterion B: maximum increase from baseline in supine diastolic BP >= 20 mmHg. Baseline was defined as the last available recording prior to dosing. | The safety analysis set included all participants who received at least 1 dose of study treatment. | Posted | Number | Participants | Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14). |
|
|
|
| Primary | Number of Participants With Vital Signs Data Meeting Categorical Criteria (Decrease From Baseline) | Number of participants with vital signs data of increase from baseline meeting the following criteria was reported: Criterion A: maximum decrease from baseline in supine systolic BP >= 30 mmHg; Criterion B: maximum decrease from baseline in supine diastolic BP >= 20 mmHg. Baseline was defined as the last available recording prior to dosing. | The safety analysis set included all participants who received at least 1 dose of study treatment. | Posted | Number | Participants | Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14). |
|
|
|
| Primary | Number of Participants With Electrocardiogram (ECG) Data Meeting Categorical Criteria (Absolute Values) | Number of participants with ECG data of absolute values meeting categorical criteria was reported as following: Criterion A: maximum PR interval (time from the beginning of P wave to the start of QRS complex, corresponding to the end of atrial depolarization and onset of ventricular depolarization) >= 300 msec; Criterion B: maximum QRS complex (time from Q wave to the end of S wave, corresponding to ventricle depolarization)>= 140 msec; Criterion C: Maximum QT interval (time from the beginning of Q wave to the end of T wave corresponding to electrical systole)>= 500 msec; Criterion D: maximum QTC interval (QT interval corrected for heart rate) 450-<480 msec; Criterion E: maximum QTC interval 480-<500 msec; Criterion F: maximum QTC interval >=500 msec; Criterion G: maximum QTCF interval (QT interval corrected for heart rate using Fridericia's formula) 450 -< 480 msec; Criterion H: maximum QTCF interval 480 -< 500 msec; Criterion I: maximum QTCF interval >=500 msec. | The safety analysis set included all participants who received at least 1 dose of study treatment. | Posted | Number | Participants | Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14). |
|
|
|
| Primary | Number of Participants With Electrocardiogram (ECG) Data Meeting Categorical Criteria (Increase From Baseline) | Number of participants with ECG Data of increase from baseline meeting the following criteria was reported: Criterion A: maximum PR interval increase from baseline percentage change (PctChg)>=25/50%; Criterion B: maximum QRS complex increase from baseline PctChg >=50%; Criterion C: maximum QTC interval (time from the beginning of Q wave to the end of T wave corresponding to electrical systole, corrected for heart rate) increase from baseline 30<=change<60 msec; Criterion D: maximum QTC interval increase from baseline change >=60 msec; Criterion E: maximum QTCF (Fridericia's correction) interval increase from baseline 30<=change<60; Criterion F: maximum QTCF interval increase from baseline change >=60 msec. Baseline was defined as the average of the triplicate measurements prior to dosing on Day 1. | The safety analysis set included all participants who received at least 1 dose of study treatment. | Posted | Number | Participants | Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14). |
|
|
|
| Primary | Number of Participants With New/Intensified Physical Examination Findings | Physical examination included examination of ears, eyes, gastrointestinal, head, heart, lungs, lymph nodes, mouth, musculoskeletal, nose, skin. The number of participants with new-intensified physical examination findings were reported. | The safety analysis set included all participants who received at least 1 dose of study treatment. | Posted | Number | Participants | Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14). |
|
|
|
| Primary | Number of Participants With New/Intensified Neurological Examination Findings | The number of participants with new-intensified neurological examination findings were reported. | The safety analysis set included all participants who received at least 1 dose of study treatment. | Posted | Number | Participants | Day 1 to follow-up visit (28 calendar days after the last dose of investigational product on Day 14). |
|
|
|
| Secondary | Maximum Plasma Concentration (Cmax) of PF-05251749 - Days 1, 7 and 14 | Maximum plasma concentration (Cmax) of PF-05251749 was observed directly from data on Days 1, 7 and 14. | The Pharmacokinetic (PK) concentration population was defined as all enrolled participants treated who received at least 1 dose of PF-05251749 and had at least 1 measureable concentration. | Posted | Geometric Mean | Geometric Coefficient of Variation | nanogram/mililiter (ng/mL) | Days 1 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h), 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h). |
|
|
|
| Secondary | Area Under the Concentration-Time Profile From Time 0 to Tau (AUCtau) of PF-05251749 - Days 1, 7 and 14. | AUCtau referred to the area under the curve from time 0 to time tau, the dosing interval, where tau equaled to 24 hours on Days 1, 7 and 14. | The PK parameter population was defined as all enrolled participants treated who received at least 1 dose of PF-05251749 and had at least 1 of the PK parameters of interest measured. | Posted | Geometric Mean | Geometric Coefficient of Variation | nanogram*hour/mililiter (ng*hr/mL) | Days 1 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h), 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h). |
|
|
|
| Secondary | Time at Which Cmax Occurred (Tmax) of PF-05251749 - Days 1, 7 and 14 | Tmax of PF-05251749 was observed directly from data on Days 1, 7 and 14, as time of first occurrence. | The PK parameter population was defined as all enrolled participants treated who received at least 1 dose of PF-05251749 and had at least 1 of the PK parameters of interest measured. | Posted | Median | Full Range | hr | Days 1 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h), 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h). |
|
|
|
| Secondary | Apparent Clearance (CL/F) of PF-05251749 - Days 7 and 14 | Apparent clearance was influenced by the fraction of the dose absorbed, which was measured by Dose/AUCtau. | The PK parameter population was defined as all enrolled participants treated who received at least 1 dose of PF-05251749 and had at least 1 of the PK parameters of interest measured. | Posted | Geometric Mean | Geometric Coefficient of Variation | Liter/hour (L/hr) | Days 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h). |
|
|
|
| Secondary | Minimum Concentration Observed (Cmin) of PF-05251749 - Days 7 and 14 | Minimum concentration observed (Cmin) of PF-05251749 was observed directly from data on Days 7 and 14. | The PK parameter population was defined as all enrolled participants treated who received at least 1 dose of PF-05251749 and had at least 1 of the PK parameters of interest measured. | Posted | Geometric Mean | Geometric Coefficient of Variation | ng/mL | Days 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h). |
|
|
|
| Secondary | Plasma Peak-to-trough Ratio (PTR) (Cmax/Cmin) of PF-05251749 - Days 7 and 14 | Peak-to-through ratio (PTR) was the ratio of Cmax to Cmin, which was measured on Days 7 and 14. | The PK parameter population was defined as all enrolled participants treated who received at least 1 dose of PF-05251749 and had at least 1 of the PK parameters of interest measured. | Posted | Geometric Mean | Geometric Coefficient of Variation | Ratio | Days 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h). |
|
|
|
| Secondary | Observed Accumulation Ratio (Rac) of PF-05251749 -Days 7 and 14 | Observed accumulation ratio (Rac) was calculated as AUCtau (Days 7 or 14) divided by AUCtau (Day 1). | The PK parameter population was defined as all enrolled participants treated who received at least 1 dose of PF-05251749 and had at least 1 of the PK parameters of interest measured. | Posted | Geometric Mean | Geometric Coefficient of Variation | Ratio | Days 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h). |
|
|
|
| Secondary | Observed Accumulation Ratio for Cmax (Rac,Cmax) of PF-05251749 - Days 7 and 14 | Observed accumulation ratio for Cmax (Rac,Cmax) was calculated as: Cmax on Day 7 or 14 divided by Cmax on Day 1. | The PK parameter population was defined as all enrolled participants treated who received at least 1 dose of PF-05251749 and had at least 1 of the PK parameters of interest measured. | Posted | Geometric Mean | Geometric Coefficient of Variation | Ratio | Days 7 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24h) and 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h). |
|
|
|
| Secondary | Terminal Half-Life (t1/2) of PF-05251749 - Day 14 | Terminal half-life (t1/2) was calculated as Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration time curve. | The PK parameter population was defined as all enrolled participants treated who received at least 1 dose of PF-05251749 and had at least 1 of the PK parameters of interest measured. | Posted | Mean | Standard Deviation | hr | Day 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h). |
|
|
|
| Secondary | Apparent Volume of Distribution (Vz/F) of PF-05251749 - Day 14 | Apparent volume of distribution (Vz/F) was calculated by Dose/(AUCtau × kel) on Day 14. | The PK parameter population was defined as all enrolled participants treated who received at least 1 dose of PF-05251749 and had at least 1 of the PK parameters of interest measured. | Posted | Geometric Mean | Geometric Coefficient of Variation | L | Day 14 (0, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 48h). |
|
|
|
| Secondary | Cumulative Amount of Drug Recovered Unchanged in Urine Over Dosing Interval Tau (Aetau) of PF-05251749 - Day 14 | Aetau was the cumulative amount of drug recovered unchanged in urine from time 0 to end of the dosing interval, which was calculated by sum of (urine concentration × volume of urine). | The PK parameter population was defined as all enrolled participants treated who received at least 1 dose of PF-05251749 and had at least 1 of the PK parameters of interest measured. | Posted | Geometric Mean | Geometric Coefficient of Variation | ng | Day 14 (0, 0.5, 1, 1.5, 2, 3, 4, 5, 8, 12, 16, 20, 24, 48h). |
|
|
|
| Secondary | Percentage of Dose Recovered Unchanged in Urine Over Dosing Interval Tau (Aetau%) of PF-05251749 - Day 14 | Aetau% was the percentage of dose recovered unchanged into urine from 0 to end of the dosing interval, which was calculated by 100 × Aetau/Dose. | The PK parameter population was defined as all enrolled participants treated who received at least 1 dose of PF-05251749 and had at least 1 of the PK parameters of interest measured. | Posted | Geometric Mean | Geometric Coefficient of Variation | Percentage of PF-05251749 | Day 14 (0, 0.5, 1, 1.5, 2, 3, 4, 5, 8, 12, 16, 20, 24, 48h). |
|
|
|
| Secondary | Renal Clearance (CLr) of PF-05251749 - Day 14 | Renal clearance was calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Ae) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau), Aetau/AUCtau. | The PK parameter population was defined as all enrolled participants treated who received at least 1 dose of PF-05251749 and had at least 1 of the PK parameters of interest measured. | Posted | Geometric Mean | Geometric Coefficient of Variation | mL/hr | Day 14 (0, 0.5, 1, 1.5, 2, 3, 4, 5, 8, 12, 16, 20, 24, 48h). |
|
|
|
| Secondary | Change From Baseline for Dim Light Melatonin Onset (DLMO) Time - Day 6 | Dim Light Melatonin Onset (DLMO) was defined as point in time when the smooth melatonin curve exceeds the threshold. The threshold for each melatonin profile was calculated as the mean of three low consecutive daytime values (raw data points) plus twice the standard deviation of these points. | The PD (pharmacodynamic) population was defined as all enrolled participants treated who provided at least 3 measurable salivary melatonin concentrations. | Posted | Mean | Standard Deviation | min | Day 0 (Baseline) and Day 6. |
|
|
|
|
| Secondary | Change From Baseline for Dim Light Melatonin Onset (DLMO) Time - Day 15 | DLMO was defined as point in time when the smooth melatonin curve exceeds the threshold. The threshold for each melatonin profile was calculated as the mean of three low consecutive daytime values (raw data points) plus twice the standard deviation of these points. | The PD population was defined as all enrolled participants treated who provided at least 3 measurable salivary melatonin concentrations. | Posted | Mean | Standard Deviation | min | Day 0 (Baseline) and Day 15 |
|
|
|
|
| 0 |
| 10 |
| 0 |
| 10 |
| 4 |
| 10 |
| EG001 | Melatonin 0.5 mg PM (Part A) | Participants received placebo suspensions matched to PF-05251749 at 08:00 AM after an overnight fast on Days 1, 7, 14 (other doses were administered outside a window of ±2 hours of giving food), and also received melatonin 0.5 mg at 06:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. | 0 | 11 | 0 | 11 | 3 | 11 |
| EG002 | PF-05251749 50 mg AM (Part A) | Participants received PF-05251749 50 mg orally at 08:00 AM after an overnight fast on Days 1, 7, 14 (other doses were administered outside a window of ±2 hours of giving food), and also received placebo capsules matched to melatonin at 06:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. | 0 | 8 | 0 | 8 | 3 | 8 |
| EG003 | PF-05251749 100 mg AM (Part A) | Participants received PF-05251749 100 mg orally at 08:00 AM after an overnight fast on Days 1, 7, 14 (other doses were administered outside a window of ±2 hours of giving food), and also received placebo capsules matched to melatonin at 06:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. | 0 | 8 | 0 | 8 | 1 | 8 |
| EG004 | PF-05251749 200 mg AM (Part A) | Participants received PF-05251749 200 mg orally at 08:00 AM after an overnight fast on Days 1, 7, 14 (other doses were administered outside a window of ±2 hours of giving food), and also received placebo capsules matched to melatonin at 06:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. | 0 | 8 | 0 | 8 | 5 | 8 |
| EG005 | PF-05251749 400 mg AM (Part A) | Participants received PF-05251749 400 mg orally at 08:00 AM after an overnight fast on Days 1, 7, 14 (other doses were administered outside a window of ±2 hours of giving food), and also received placebo capsules matched to melatonin at 06:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. | 0 | 8 | 0 | 8 | 7 | 8 |
| EG006 | PF-05251749 750 mg AM (Part A) | Participants received PF-05251749 750 mg orally at 08:00 AM after an overnight fast on Days 1, 7, 14 (other doses were administered outside a window of ±2 hours of giving food), and also received placebo capsules matched to melatonin at 06:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. | 0 | 8 | 0 | 8 | 7 | 8 |
| EG007 | Placebo (Part B) | Participants received placebo suspensions matched to PF-05251749 at 6:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. | 0 | 12 | 0 | 12 | 3 | 12 |
| EG008 | PF-05251749 50 mg PM (Part B) | Participants received PF-05251749 50 mg orally at 6:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. | 0 | 8 | 1 | 8 | 4 | 8 |
| EG009 | PF-05251749 200 mg PM (Part B) | Participants received PF-05251749 200 mg orally at 6:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. | 0 | 8 | 0 | 8 | 2 | 8 |
| EG010 | PF-05251749 500 mg PM (Part B) | Participants received PF-05251749 500 mg orally at 6:00 PM outside a window of ±2 hours of giving food. Dosing continued every day until the final dose was administered on Day 14. | 0 | 8 | 0 | 8 | 8 | 8 |
| Constipation | Gastrointestinal disorders | MedDRA 20.0 | Non-systematic Assessment |
|
| Diarrhoea | Gastrointestinal disorders | MedDRA 20.0 | Non-systematic Assessment |
|
| Dyspepsia | Gastrointestinal disorders | MedDRA 20.0 | Non-systematic Assessment |
|
| Frequent bowel movements | Gastrointestinal disorders | MedDRA 20.0 | Non-systematic Assessment |
|
| Nausea | Gastrointestinal disorders | MedDRA 20.0 | Non-systematic Assessment |
|
| Toothache | Gastrointestinal disorders | MedDRA 20.0 | Non-systematic Assessment |
|
| Chills | General disorders | MedDRA 20.0 | Non-systematic Assessment |
|
| Pharyngitis | Infections and infestations | MedDRA 20.0 | Non-systematic Assessment |
|
| Upper respiratory tract infection | Infections and infestations | MedDRA 20.0 | Non-systematic Assessment |
|
| Urinary tract infection | Infections and infestations | MedDRA 20.0 | Non-systematic Assessment |
|
| Alanine aminotransferase increased | Investigations | MedDRA 20.0 | Non-systematic Assessment |
|
| Blood creatine phosphokinase increased | Investigations | MedDRA 20.0 | Non-systematic Assessment |
|
| Electrocardiogram T wave inversion | Investigations | MedDRA 20.0 | Non-systematic Assessment |
|
| Haemoglobin decreased | Investigations | MedDRA 20.0 | Non-systematic Assessment |
|
| Hepatic enzyme abnormal | Investigations | MedDRA 20.0 | Non-systematic Assessment |
|
| Hepatic enzyme increased | Investigations | MedDRA 20.0 | Non-systematic Assessment |
|
| White blood cell count decreased | Investigations | MedDRA 20.0 | Non-systematic Assessment |
|
| Dizziness | Nervous system disorders | MedDRA 20.0 | Non-systematic Assessment |
|
| Headache | Nervous system disorders | MedDRA 20.0 | Non-systematic Assessment |
|
| Presyncope | Nervous system disorders | MedDRA 20.0 | Non-systematic Assessment |
|
| Insomnia | Psychiatric disorders | MedDRA 20.0 | Non-systematic Assessment |
|
| Hyperhidrosis | Skin and subcutaneous tissue disorders | MedDRA 20.0 | Non-systematic Assessment |
|
| Pruritus | Skin and subcutaneous tissue disorders | MedDRA 20.0 | Non-systematic Assessment |
|
| Palpitations | Cardiac disorders | MedDRA 20.0 | Non-systematic Assessment |
|
| Haematuria | Renal and urinary disorders | MedDRA 20.0 | Non-systematic Assessment |
|
| Hot flush | Vascular disorders | MedDRA 20.0 | Non-systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | MedDRA 20.0 | Non-systematic Assessment |
|
| Decreased appetite | Metabolism and nutrition disorders | MedDRA 20.0 | Non-systematic Assessment |
|
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
| D006571 | Heterocyclic Compounds |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
|
|
|
|
|
|
|
|
|
| Day 4 (1.5h) |
|
|
| Day 7 (0h) |
|
|
| Day 7 (2h) |
|
|
| Day 10 (1.5h) |
|
|
| Day 14 (0h) |
|
|
| Day 14 (2h) |
|
|
| Day 15 (0h) |
|
|
| Day 16 (0h) |
|
|
|
| Day 4 (1.5h) |
|
|
| Day 7 (0h) |
|
|
| Day 7 (2h) |
|
|
| Day 10 (1.5h) |
|
|
| Day 14 (0h) |
|
|
| Day 14 (2h) |
|
|
| Day 15 (0h) |
|
|
| Day 16 (0h) |
|
|
| Day 7 |
|
| Day 14 |
|
| Day 16 |
|
| Follow-up |
|
| Supine Diastolic BP < 50 mmHg |
|
| Supine Pulse Rate < 40 BPM |
|
| Supine Pulse Rate > 120 BPM |
|
| Criterion B |
|
| Criterion B |
|
| Criterion B |
|
| Criterion C |
|
| Criterion D |
|
| Criterion E |
|
| Criterion F |
|
| Criterion G |
|
| Criterion H |
|
| Criterion I |
|
| Criterion B |
|
| Criterion C |
|
| Criterion D |
|
| Criterion E |
|
| Criterion F |
|
|
| Day 7 |
|
|
| Day 14 |
|
|
|
| Day 7 |
|
|
| Day 14 |
|
|
|
| Day 7 |
|
|
| Day 14 |
|
|
|
| Day 14 |
|
|
|
| Day 14 |
|
|
|
| Day 14 |
|
|
|
| Day 14 |
|
|
|
| Day 14 |
|
|
| Mean Difference (Final Values) |
| -27.13 |
| Standard Error of the Mean |
| 38.61 |
| 2-Sided |
| 90 |
| -91.24 |
| 36.97 |
Test (PF-05251749 50 mg AM) Reference (Placebo) |
| Other |
MMRM |
| Mean Difference (Final Values) | 43.72 | Standard Error of the Mean | 45.72 | 2-Sided | 90 | -32.19 | 119.62 | Test (PF-05251749 100 mg AM) Reference (Placebo) | Other | MMRM |
| Mean Difference (Final Values) | 61.48 | Standard Error of the Mean | 40.88 | 2-Sided | 90 | -6.38 | 129.35 | Test (PF-05251749 200 mg AM) Reference (Placebo) | Other | MMRM |
| Mean Difference (Final Values) | 125.87 | Standard Error of the Mean | 39.37 | 2-Sided | 90 | 60.51 | 191.23 | Test (PF-05251749 400 mg AM) Reference (Placebo) | Other | MMRM |
| Mean Difference (Final Values) | 156.22 | Standard Error of the Mean | 42.91 | 2-Sided | 90 | 84.99 | 227.45 | Test (PF-05251749 750 mg AM) Reference (Placebo) | Other | MMRM |
| Mean Difference (Final Values) | 51.42 | Standard Error of the Mean | 33.12 | 2-Sided | 90 | -3.57 | 106.41 | Test (PF-05251749 50 mg PM) Reference (Placebo) | Other | MMRM |
| Mean Difference (Final Values) | 142.74 | Standard Error of the Mean | 36.13 | 2-Sided | 90 | 82.76 | 202.72 | Test (PF-05251749 200 mg PM) Reference (Placebo) | Other | MMRM |
| Mean Difference (Final Values) | 174.90 | Standard Error of the Mean | 36.01 | 2-Sided | 90 | 115.11 | 234.69 | Test (PF-05251749 500 mg PM) Reference (Placebo) | Other | MMRM |
| Mean Difference (Final Values) |
| -12.13 |
| Standard Error of the Mean |
| 38.61 |
| 2-Sided |
| 90 |
| -76.24 |
| 51.97 |
Test (PF-05251749 50 mg AM) Reference (Placebo) |
| Other |
MMRM |
| Mean Difference (Final Values) | 88.72 | Standard Error of the Mean | 45.72 | 2-Sided | 90 | 12.81 | 164.62 | Test (PF-05251749 100 mg AM) Reference (Placebo) | Other | MMRM |
| Mean Difference (Final Values) | 46.48 | Standard Error of the Mean | 40.88 | 2-Sided | 90 | -21.38 | 114.35 | Test (PF-05251749 200 mg AM) Reference (Placebo) | Other | MMRM |
| Mean Difference (Final Values) | 87.30 | Standard Error of the Mean | 39.37 | 2-Sided | 90 | 21.94 | 152.66 | Test (PF-05251749 400 mg AM) Reference (Placebo) | Other | MMRM |
| Mean Difference (Final Values) | 126.22 | Standard Error of the Mean | 42.91 | 2-Sided | 90 | 54.99 | 197.45 | Test (PF-05251749 750 mg AM) Reference (Placebo) | Other | MMRM |
| Mean Difference (Final Values) | 92.36 | Standard Error of the Mean | 35.48 | 2-Sided | 90 | 33.51 | 151.21 | Test (PF-05251749 50 mg PM) Reference (Placebo) | Other | MMRM |
| Mean Difference (Final Values) | 107.29 | Standard Error of the Mean | 36.13 | 2-Sided | 90 | 47.31 | 167.27 | Test (PF-05251749 200 mg AM) Reference (Placebo) | Other | MMRM |
| Mean Difference (Final Values) | 140.61 | Standard Error of the Mean | 37.79 | 2-Sided | 90 | 77.91 | 203.30 | Test (PF-05251749 500 mg AM) Reference (Placebo) | Other | MMRM |